News

Out of the funding, nearly €4.3m has been given directly to BioAlliance Pharma to hasten the industrial development of Livatag, a doxorubicin nanoparticle currently under phase III trial

Cancer Research UK policy and information executive director Sarah Woolnough said that the initiative should help save more lives from cancer in the future. "Crucially, it means unearthing

Commencement of the study using the platform has triggered a milestone payment for BioInvent, as per its collaboration agreement with partners who finance the development of the new

Qsymia is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of

Developed under a co-development and commercialization agreement between Genmab and GSK, Ofatumumab is a human monoclonal antibody which targets an epitope on the CD20 molecule encompassing parts of

A clotting factor, Eloctate is under development using Biogen Idec’s novel and proprietary monomeric Fc fusion technology. Announced at the XXIV International Society on Thrombosis and Haemostasis (ISTH)

Sources familiar with the potential deal were quoted by Bloomberg as saying that the purchase was yet to be finalized and that a decision would be taken as

The deployment includes Mobile Intelligence for tablets, MI Touch, and Mobile Intelligence for PCs, MI PC Relevant Products/Services. These tablets and PCs are powered by onekey database which

Granted through bpifrance’s Strategic Industrial Innovation (ISI) program, the funding is to expedite the clinical and industrial development of NBTXR3 in a new indication, liver cancer. Liver cancer